Sumithra J. Mandrekar
Genetics · 2005–2018
A researcher in the Science corpus: 7 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Genetics — 12 citations into it
- Statistics and Probability — 8 citations into it
Whom Sumithra J. Mandrekar trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Sumithra J. Mandrekar's perspective
Ordered by how strongly the researchers Sumithra J. Mandrekar trusts endorse each paper. Same corpus, a different order for every researcher.
- New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia (New England Journal of Medicine)
- Lung cancer screening with CT: Mayo Clinic experience. (Radiology)
- Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. (Cancer Cell)
- Bayesian clinical trials
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
- Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. (Journal of Clinical Oncology)
- Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. (Journal of the National Cancer Institute)
- Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. (Journal of the American Medical Association (JAMA))
- Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers (Journal of Neuroscience)
Their papers
- Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials (2011) — 383 citations
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (2018) — 816 citations
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (2017) — 2,028 citations
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) — 1,974 citations
- Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials (2017) — 155 citations
- RECIST 1.1 – Update and Clarification: From the RECIST Committee (2016) — 1,774 citations
- CT screening for lung cancer: five-year prospective experience. (2005) — 600 citations